Renal Cell Carcinoma

Findings from the phase 3 CLEAR trial showed that the addition of lenvatinib to either pembrolizumab or everolimus led to an improvement in survival and response rates in comparison with sunitinib monotherapy in the first-line setting for patients with advanced renal cell carcinoma.

The addition of the oral hypoxia-inducible factor 2α inhibitor belzutifan to cabozantinib led to disease control in a majority of patients with previously treated advanced clear cell renal cell carcinoma, according to preliminary results from a phase 2 trial presented at the 2021 Genitourinary Cancers Symposium.

Cabozantinib reduced the risk of disease progression or death by 40% in comparison with sunitinib in patients with metastatic papillary renal cell carcinoma, according to findings from the randomized phase 2 SWOG 1500 study.

In patient with metastatic renal cell carcinoma who have brain metastases, treatment with cabozantinib displayed significant intracranial and extracranial, results from a retrospective analysis presented during the 2021 Genitourinary Cancers Symposium show.

Nivolumab in combination with cabozantinib continues to demonstrate superior efficacy over sunitinib monotherapy in the frontline treatment of patients with advanced renal cell carcinoma, according to extended follow-up data from the phase 3 CheckMate 9ER trial.

The VEGF tyrosine kinase inhibitor tivozanib hydrochloride demonstrated a significantly increased quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy in patients with metastatic renal cell carcinoma compared with sorafenib in the phase 3 TIVO-3 trial.

Nivolumab plus cabozantinibreportedly improved health-related quality of life for patients with advanced renal cell carcinoma when compared to treatment with sunitinib.

A retrospective study has suggested that immunotherapy may have a great survival benefit in the frontline setting for patients with metastatic non–clear cell renal cell carcinoma (RCC) than select targeted therapies.

In patients with clear cell renal cell carcinoma who had been treated with an immune checkpoint inhibitor in prior lines of therapy, lenvatinib in combination with everolimus was found to be safe and effective.

Ulka N. Vaishampayan, MBBS, FAB, discusses the updated data from CheckMate 214 of nivolumab and ipilimumab versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

In an interview with Targeted Oncology, Andrea Apolo, MD discussed the impact of the combination of nivolumab and cabozantinib as a new treatment for patients with advanced renal cell carcinoma.

The FDA has granted approval to the combination of nivolumab and cabozantinib as treatment of advanced renal cell carcinoma in the frontline setting.

Elizabeth Wulff-Burchfield, MD, discusses the role of immune checkpoint inhibitor combination therapy in metastatic renal cell carcinoma.

The role of immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors appear encouraging for the treatment of patients with kidney cancer following recent research on targeting von Hippel-Lindau disease-associated renal cell carcinoma.

Pazopanib, a tyrosine kinase inhibitor, is active and well-tolerated in patients with poor-risk metastatic clear cell renal cell carcinoma with no new safety signal observed, according to results from the phase 4 FLIPPER clinical trial.

Treatment with telaglenastat in combination with cabozantinib did not improve progression-free survival in patients with advanced or metastatic renal cell carcinoma when compared with cabozantinib alone, missing the primary end point of the phase 2 CANTANA clinical trial.

Treatment with MK-6482, an investigational HIF2α inhibitor, demonstrated durable efficacy as treatment of patients with Von Hippel-Lindau-associated renal cell carcinoma and non-renal lesions, according to phase 2 data presented during the 21st Annual Meeting of the Society of Urologic Oncology.

The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau disease-associated clear cell renal cell carcinoma and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology.

Toni Choueiri, MD, discusses nivolumab, ipilimumab, and cabozantinib combinations in ongoing phase 3 trials as treatment for patients with advanced renal cell carcinoma.

During a Targeted Oncology Case Based Peer Perspectives event, Marc Matrana, MD, MS, discussed the case of a 62-year-old male patients with renal cell carcinoma.

In an interview with Targeted Oncology, Chung-Han (Joe) Lee, MD, PhD, discussed the use of different targeted therapy and immunotherapy strategies for the treatment of patients with metastatic kidney cancer.

In an interview with Targeted Oncology, Thomas E. Hutson, DO, PharmD, discussed the difficult-to-treat nccRCC patient population and the promise of lenvatinib plus everolimus, as well as other combination regimens.

Lenvatinib in combination with everolimus improved progression-free survival in patients with advanced renal cell carcinoma compared with sunitinib, meeting the primary end point of the phase 3 KEYNOTE-581/CLEAR clinical trial. Pembrolizumab added to lenvatinib, another experimental arm of the trial, also achieved a satisfactory overall response rate, meeting a key secondary end point.

Investigators of the CheckMate 920 trial found no differences in safety signals or responses with modified dosing of nivolumab and ipilimumab compared with the standard dose in patients with advanced renal cell carcinoma treated in the frontline.

During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.